Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
NCT ID: NCT01358695
Last Updated: 2013-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
111 participants
INTERVENTIONAL
2011-05-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BOTOX® in the Treatment of Crow's Feet Lines in China
NCT02195687
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
NCT01809964
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
NCT03655691
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01776606
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01940991
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Comparator
ANT-1207
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Dose 1
Dose 1
ANT-1207
The interventions differ by dose of investigational product applied.
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Dose 2
Dose 2
ANT-1207
The interventions differ by dose of investigational product applied.
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Dose 3
Dose 3
ANT-1207
The interventions differ by dose of investigational product applied.
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Dose 4
Dose 4
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Dose 5
Dose 5
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANT-1207
The interventions differ by dose of investigational product applied.
Botulinum Toxin, Type A
The interventions differ by dose of investigational product applied.
Botulinum Toxin Type A
The interventions differ by dose of investigational product applied.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* moderate to severe Crow's Feet (IGA 3-4) on contraction
* willingness to refrain from any product affecting skin remodeling
* female subjects must be not pregnant and non-lactating
Exclusion Criteria
* procedures affecting the lateral canthal region in the prior 12 months
* application of topical prescription medication to the treatment area
* female subjects who are pregnant or are nursing a child
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anterios Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Total Skin & Beauty Dermatology Center
Birmingham, Alabama, United States
Baumann Cosmetic & Research Institute
Miami Beach, Florida, United States
Palm Beach Esthetic Dermatology and Laser Center
West Palm Beach, Florida, United States
William Coleman III, MD, APMC
Metairie, Louisiana, United States
Gramercy Park Dermatology
New York, New York, United States
Cary Skin Care
Cary, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANT-1207-201-LCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.